O6-Methylguanine-DNA Methyltransferase (MGMT): Challenges and New Opportunities in Glioma Chemotherapy

Overview of DNA methylation in adult diffuse gliomas

(2019) Kosuke Aoki et al.   Brain Tumor Pathology

Posttreatment Effect of MGMT Methylation Level on Glioblastoma Survival

(2019) Rikke H Dahlrot et al.   JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY

DNA repair in personalized brain cancer therapy with temozolomide and nitrosoureas

(2019) Bernd Kaina et al.   DNA REPAIR

Gene promoter methylation and cancer: An umbrella review

(2019) Emmanouil Bouras et al.   GENE

Clinical and Prognostic Significance of O6-Methylguanine-DNA Methyltransferase Promoter Methylation in Patients with Melanoma: A Systematic Meta-Analysis

(2018) Fang Qi et al.   Annals of Dermatology

Outlining involvement of stem cell program in regulation of O6-methylguanine DNA methyltransferase and development of temozolomide resistance in glioblastoma

(2018) Anastasia Chumakova et al.   JOURNAL OF NEUROCHEMISTRY

Transcriptional control of O6 -methylguanine DNA methyltransferase expression and temozolomide resistance in glioblastoma

(2018) Caroline Happold et al.   JOURNAL OF NEUROCHEMISTRY

Repair gene O6 -methylguanine-DNA methyltransferase is controlled by SP1 and up-regulated by glucocorticoids, but not by temozolomide and radiation

(2018) Dorthe Aasland et al.   JOURNAL OF NEUROCHEMISTRY

MGMT promoter methylation is not correlated with integrin expression in malignant gliomas: clarifying recent clinical trial results

(2018) Oliver Schnell et al.   MEDICAL ONCOLOGY

MGMT assessment in pituitary adenomas: comparison of different immunohistochemistry fixation chemicals

(2018) Alexander S. G. Micko et al.   Pituitary

Concordant association validates MGMT methylation and protein expression as favorable prognostic factors in glioma patients on alkylating chemotherapy (Temozolomide)

(2018) Arshad A. Pandith et al.   Scientific Reports

Epigenetic Targeting of Glioblastoma

(2018) Massimo Romani et al.   Frontiers in Oncology

Chemotherapy sensitization of glioblastoma by focused ultrasound-mediated delivery of therapeutic liposomes

(2018) Alexandros Papachristodoulou et al.   JOURNAL OF CONTROLLED RELEASE

MiR-198 enhances temozolomide sensitivity in glioblastoma by targeting MGMT

(2017) Er Nie et al.   JOURNAL OF NEURO-ONCOLOGY

Comparative assessment of three methods to analyze MGMT methylation status in a series of 350 gliomas and gangliogliomas

(2017) Leiming Wang et al.   PATHOLOGY RESEARCH AND PRACTICE

RTOG 0525: A randomized phase III trial comparing standard adjuvant temozolomide (TMZ) with a dose-dense (dd) schedule in newly diagnosed glioblastoma (GBM).

(2017) M. R. Gilbert et al.   JOURNAL OF CLINICAL ONCOLOGY

Uptake of glucose-conjugated MGMT inhibitors in cancer cells: role of flippases and type IV P-type ATPases

(2017) Karl-Heinz Tomaszowski et al.   Scientific Reports

Corticosteroids compromise survival in glioblastoma

(2016) Kenneth L. Pitter et al.   BRAIN

MGMT promoter methylation determined by HRM in comparison to MSP and pyrosequencing for predicting high-grade glioma response

(2016) Olivier J. Switzeny et al.   Clinical Epigenetics

Impact on prognosis of the regional distribution of MGMT methylation with respect to the CpG island methylator phenotype and age in glioma patients

(2015) Pilar Mur et al.   JOURNAL OF NEURO-ONCOLOGY

Multidrug Efflux Pumps Attenuate the Effect of MGMT Inhibitors

(2015) Karl-Heinz Tomaszowski et al.   MOLECULAR PHARMACEUTICS

Apoptosis induced by temozolomide and nimustine in glioblastoma cells is supported by JNK/c-Jun-mediated induction of the BH3-only protein BIM

(2015) Maja T. Tomicic et al.   Oncotarget

MGMT promoter methylation and correlation with protein expression in primary central nervous system lymphoma

(2014) L. Toffolatti et al.   VIRCHOWS ARCHIV

Disulfiram is a direct and potent inhibitor of human O6-methylguanine-DNA methyltransferase (MGMT) in brain tumor cells and mouse brain and markedly increases the alkylating DNA damage

(2013) A. Paranjpe et al.   CARCINOGENESIS

Transcriptional/epigenetic regulator CBP/p300 in tumorigenesis: structural and functional versatility in target recognition

(2013) Feng Wang et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

O6-methylguanine-DNA methyltransferase (MGMT) immunohistochemistry as a predictor of resistance to temozolomide in primary CNS lymphoma

(2013) Xiaoyin Jiang et al.   JOURNAL OF NEURO-ONCOLOGY

YB-1 dependent oncolytic adenovirus efficiently inhibits tumor growth of glioma cancer stem like cells

(2013) Klaus Mantwill et al.   Journal of Translational Medicine

MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status

(2012) Pierre Bady et al.   ACTA NEUROPATHOLOGICA

MGMT testing for glioma in clinical laboratories: discordance with methylation analyses prevents the implementation of routine immunohistochemistry

(2012) Sofia Mason et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy

(2012) Consolación Melguizo et al.   Journal of Translational Medicine

Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial

(2012) Annika Malmström et al.   LANCET ONCOLOGY

Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial

(2012) Wolfgang Wick et al.   LANCET ONCOLOGY

miR-181d: a predictive glioblastoma biomarker that downregulates MGMT expression

(2012) W. Zhang et al.   NEURO-ONCOLOGY

A distinct region of the MGMT CpG island critical for transcriptional regulation is preferentially methylated in glioblastoma cells and xenografts

(2011) Deborah S. Malley et al.   ACTA NEUROPATHOLOGICA

Inhibition of DNA repair with MGMT pseudosubstrates: phase I study of lomeguatrib in combination with dacarbazine in patients with advanced melanoma and other solid tumours

(2011) H A Tawbi et al.   BRITISH JOURNAL OF CANCER

Correlation of MGMT promoter methylation status with gene and protein expression levels in glioblastoma

(2011) Miyuki Uno et al.   Clinics

Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas

(2011) Jörg Felsberg et al.   INTERNATIONAL JOURNAL OF CANCER

Predictive impact of MGMT promoter methylation in glioblastoma of the elderly

(2011) Guido Reifenberger et al.   INTERNATIONAL JOURNAL OF CANCER

Oncolytic Virus-Mediated Manipulation of DNA Damage Responses: Synergy With Chemotherapy in Killing Glioblastoma Stem Cells

(2011) Ryuichi Kanai et al.   JNCI-Journal of the National Cancer Institute

O6-methylguanine DNA-methyltransferase methylation status can change between first surgery for newly diagnosed glioblastoma and second surgery for recurrence: clinical implications

(2011) A. A. Brandes et al.   NEURO-ONCOLOGY

Tumor O6-methylguanine-DNA Methyltransferase Inactivation by Oral Lomeguatrib

(2010) A. J. Watson et al.   CLINICAL CANCER RESEARCH

Efficient delivery of liposome-mediated MGMT-siRNA reinforces the cytotoxity of temozolomide in GBM-initiating cells

(2010) T Kato et al.   GENE THERAPY

MGMT activity, promoter methylation and immunohistochemistry of pretreatment and recurrent malignant gliomas: a comparative study on astrocytoma and glioblastoma

(2010) Markus Christmann et al.   INTERNATIONAL JOURNAL OF CANCER

Intratumoral Hypoxic Gradient Drives Stem Cells Distribution and MGMT Expression in Glioblastoma

(2010) Francesca Pistollato et al.   STEM CELLS

O6-methylguanine-DNA methyltransferase depletion and DNA damage in patients with melanoma treated with temozolomide alone or with lomeguatrib

(2009) A J Watson et al.   BRITISH JOURNAL OF CANCER

Phase II Trial of Gliadel plus O6-Benzylguanine in Adults with Recurrent Glioblastoma Multiforme

(2009) J. A. Quinn et al.   CLINICAL CANCER RESEARCH

MGMTPromoter Methylation Is Prognostic but Not Predictive for Outcome to Adjuvant PCV Chemotherapy in Anaplastic Oligodendroglial Tumors: A Report From EORTC Brain Tumor Group Study 26951

(2009) Martin J. van den Bent et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Trial of Temozolomide Plus O6-Benzylguanine in Adults With Recurrent, Temozolomide-Resistant Malignant Glioma

(2009) Jennifer A. Quinn et al.   JOURNAL OF CLINICAL ONCOLOGY

NOA-04 Randomized Phase III Trial of Sequential Radiochemotherapy of Anaplastic Glioma With Procarbazine, Lomustine, and Vincristine or Temozolomide

(2009) Wolfgang Wick et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma

(2009) Jennifer A. Quinn et al.   NEURO-ONCOLOGY

Identification of regions correlating MGMT promoter methylation and gene expression in glioblastomas

(2009) Sibille Everhard et al.   NEURO-ONCOLOGY

Anti-O6-Methylguanine-Methyltransferase (MGMT) Immunohistochemistry in Glioblastoma Multiforme: Observer Variability and Lack of Association with Patient Survival Impede Its Use as Clinical Biomarker

(2008) Matthias Preusser et al.   BRAIN PATHOLOGY

O6-Methylguanine-DNA methyltransferase inactivation and chemotherapy

(2008) B. Verbeek et al.   BRITISH MEDICAL BULLETIN

Temozolomide Preferentially Depletes Cancer Stem Cells in Glioblastoma

(2008) D. Beier et al.   CANCER RESEARCH